Evotec offers to acquire cyprotex
WebOct 26, 2016 · HAMBURG, Germany--(BUSINESS WIRE)--Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) today announced that it has made an offer to acquire Cyprotex PLC (AIM Listing: CRX-GB), a specialist pre-clinical contract research organisation in ADME-Tox and DMPK headquartered in … WebOct 26, 2016 · Evotec AG today announced that it has made an offer to acquire Cyprotex PLC , a specialist... January 20, 2024
Evotec offers to acquire cyprotex
Did you know?
WebOct 26, 2016 · DGAP-News: Evotec AG / Key word(s): Mergers & Acquisitions2016-10-26 / 09:12The issuer is solely responsible for the content of this announcement.----- Acquisition would add world-leading high-quality ADME-Tox services andstrengthen Evotec's leadership in drug discovery- Evotec will pay approximately £ 55.36 m (EUR 62. ... WebOct 26, 2016 · Evotec will pay approximately £ 55.36 m (EUR 62.00 m; £/EUR exchange rate of 1.12) in cash for the acquisition of all 26.1 million issued and to be issued Cyprotex shares and the funding of all ...
WebOct 26, 2016 · - Acquisition would add world-leading high-quality ADME-Tox services and strengthen Evotec's leadership in drug discovery - Evotec will pay approximately £ … WebCyprotex’s customers will now be able to access Evotec’s integrated and standalone drug discovery services and the acquisition expands Cyprotex’s service portfolio to include medicinal chemistry, structural biology and in vitro and in vivo pharmacology services. Evotec can also offer specialist expertise in key therapeutic areas such as ...
WebDec 15, 2016 · Acquisition of 100% shares in Cyprotex PLC effective 14 December 2016; Evotec is paying £ 55.7 m in cash for the full share capital of Cyprotex and funding of … WebNov 4, 2024 · Evotec SE today announced the signing of a definitive agreement under which Evotec will acquire 100% of the capital of Rigenerand Srl, a leading cell technology company, for a purchase price of € 23 m. ... Evotec AG today announced that it has made an offer to acquire Cyprotex PLC ("Cyprotex", AIM: CRX-GB), a specialist pre-clinical …
WebOct 26, 2016 · - Acquisition would add world-leading high-quality ADME-Tox services and strengthen Evotec's leadership in drug discovery - Evotec will pay approximately £ 55.36 m in... April 9, 2024
WebOct 26, 2016 · Data & APIs. Events. Marketfy embryo becomes a fetus after weekWebAbout us. Founded in 1999, Cyprotex (www.cyprotex.com) has grown to become an industry leader in in vitro and in silico ADME-Tox. The company, with sites in the UK and … embryo crosswordWebOct 26, 2016 · The offer of 1.60 £ per Cyprotex share reflects a 9.4% premium to the VWAP of the past 30 trading days at AIM. The offer is intended to be implemented by a scheme of arrangement regulated by the UK takeover code, with already >50% shares secured irrevocable. The acquisition will add to Evotec’s revenues and be accretive to … embryo attaching to uterus wall symptomsWebFeb 15, 2024 · Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that Cyprotex US, LLC, the US site of Cyprotex a wholly owned subsidiary of Evotec, has completed its relocation from Watertown, MA to a new state-of-the-art facility in Framingham, MA, paving the way for … embryo attrition ivfembryo becomes fetusWebYou have not yet registered? Get your account for free. Register Here embryo characteristicWeb22 rows · Oct 26, 2016 · The offer of 1.60 £ per Cyprotex share reflects a 9.4% premium to the VWAP of the past 30 ... With Evotec, a smart idea can unfold and mature, with the help of our many … The Evotec collection. Evotec’s library contains 450,000 compounds consisting … Evotec offers services and alliances based on its state-of-the-art technology … In this section you can find Evotec's current "Conditions of Purchase" available for … Evotec’s mission is to discover and develop highly effective therapeutics and make … embryo cleavage rate